GS 7977 (Gilead) success in Phase II studies in HCV

In a Phase II study conducted among pre-transplant Hepatitis C (HCV) patients (Study 2025), up to 48 weeks of GS 7977 (sofosbuvir), from Gilead Sciences, plus ribavirin (RBV) therapy was administered. Among patients with undetectable HCV (<25 iu ml at the time of transplantation 64 percent n="25/39)" achieved undetectable hcv rna 12 weeks post-transplant ptvr12. patients who achieve ptvr12 are considered cured of hcv infection.>

In a second study conducted among post-transplant HCV patients (Study 126), patients with established recurrent HCV infection following liver transplantation received 24 weeks of sofosbuvir/RBV therapy. Seventy-seven percent (n=27/35) of patients in this study have achieved a sustained virologic response four weeks posttreatment (SVR4). Three percent and five percent of patients discontinued treatment due to adverse events in the pre- and post-transplant studies, respectively. No serious adverse events reported. Data were presented at the AASLD's Liver Meeting.